Glaukos begins commercialization of iStent inject — 5 highlights

Glaukos has created a direct organization and initiated the commercial launch of the iStent inject Trabecular Micro-Bypass Stent in Canada.

Here are five highlights:

1. The iStent inject system is preloaded with two micro-scale stents that the surgeon places through a single corneal entry point directly into the eye’s drainage canal to restore the natural, physiological outflow of fluid and reduce intraocular pressure.

2. The iStent inject is designed to allow placement of stents into multiple trabecular meshwork locations with a straightforward click-and-release motion.

3. Each iStent inject stent is approximately 0.3 mm in diameter and 0.4 mm long and is made from surgical-grade non-ferromagnetic titanium coated with heparin.

4. The iStent inject is approved by Health Canada for IOP reduction in patients diagnosed with primary open angle glaucoma, pseudo exfoliative glaucoma or pigmentary glaucoma, and may be used in combination with cataract surgery or in a standalone procedure.

5. Glaukos is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast